Meningococcal vaccine groups A B C Y W-135 conjugate - GSK
Alternative Names: GSK-3536819A; GSK3536819; MenABCWY (1st Gen); Meningococcal ABCWY Vaccine; rMenB + MenACWYLatest Information Update: 24 May 2024
At a glance
- Originator Novartis
- Developer GSK
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 16 Apr 2024 Preregistration for Meningococcal group A infections (In adolescents, In children, Prevention, In adults) in USA (IM)
- 16 Apr 2024 Preregistration for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in USA (IM)
- 16 Apr 2024 Preregistration for Meningococcal group C infections (In adolescents, In children, Prevention, In adults) in USA (IM)